Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07779460 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07779460 · ClinicalTrials.gov record · last posted 2026-08-21

A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice

Name: A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice — clinical trial record (NCT07779460)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhaseNot specified

SponsorNovartis Pharmaceuticals

Started2026-04-08

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study aims to generate real-world evidence on the clinical effectiveness and economic burden of ofatumumab (OMB) versus ocrelizumab (OCR) in patients diagnosed with multiple sclerosis (MS) in the United States (US). Clinical effectiveness will be assessed using annualized relapse rate (ARR), while economic burden will be assessed using healthcare resource utilization (HCRU) and healthcare costs (HCC). This study will use two primary data sources that capture longitudinal, de-identified healthcare utilization derived from claims submitted for reimbursement.

Trial Details

NCT Number	NCT07779460
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Multiple Sclerosis
Enrollment	7,466 participants
Start Date	2026-04-08
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-21